Have a feature idea you'd love to see implemented?
Let us know!
UBX Unity Biotechnology Inc
Price (delayed)
$1.16
Market cap
$19.55M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.07
Enterprise value
$31.35M
UNITY is developing a new class of therapeutics to slow, halt or reverse diseases of aging. UNITY's current focus is on creating medicines to selectively eliminate or modulate senescent cells
Highlights
UBX's net income is up by 44% YoY and by 30% from the previous quarter
The EPS is up by 37% since the previous quarter and by 21% year-on-year
UBX's equity has dropped by 61% year-on-year and by 28% since the previous quarter
The quick ratio has contracted by 38% YoY and by 14% from the previous quarter
Key stats
What are the main financial stats of UBX
Market
Valuations
Earnings
Shares outstanding
16.85M
Market cap
$19.55M
Enterprise value
$31.35M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.38
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
$0
EBIT
-$19.05M
EBITDA
-$18.15M
Free cash flow
-$22.4M
Per share
Balance sheet
Liquidity
EPS
-$1.07
Free cash flow per share
-$1.33
Book value per share
$0.84
Revenue per share
$0
TBVPS
$2.8
Total assets
$47.13M
Total liabilities
$32.99M
Debt
$20.7M
Equity
$14.14M
Working capital
$21.48M
Debt to equity
1.46
Current ratio
3.45
Quick ratio
3.31
Net debt/EBITDA
-0.65
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
-33.8%
Return on equity
-88.3%
Return on invested capital
-32.2%
Return on capital employed
-49.7%
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
UBX stock price
How has the Unity Biotechnology stock price performed over time
Intraday
-0.85%
1 week
-7.94%
1 month
-17.14%
1 year
-43.69%
YTD
-39.9%
QTD
-21.09%
Financial performance
How have Unity Biotechnology's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$28.3M
Net income
-$19.05M
Gross margin
N/A
Net margin
N/A
UBX's operating income is up by 44% year-on-year and by 22% since the previous quarter
UBX's net income is up by 44% YoY and by 30% from the previous quarter
Growth
What is Unity Biotechnology's growth rate over time
Valuation
What is Unity Biotechnology stock price valuation
P/E
N/A
P/B
1.38
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The EPS is up by 37% since the previous quarter and by 21% year-on-year
UBX's equity has dropped by 61% year-on-year and by 28% since the previous quarter
The P/B is 27% less than the 5-year quarterly average of 1.9 but 15% more than the last 4 quarters average of 1.2
Efficiency
How efficient is Unity Biotechnology business performance
UBX's return on equity is down by 29% year-on-year but it is up by 13% since the previous quarter
UBX's ROA is up by 24% since the previous quarter
UBX's ROIC is up by 21% since the previous quarter but it is down by 14% year-on-year
Dividends
What is UBX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for UBX.
Financial health
How did Unity Biotechnology financials performed over time
UBX's total assets is 43% greater than its total liabilities
The current ratio fell by 40% YoY and by 15% QoQ
The quick ratio has contracted by 38% YoY and by 14% from the previous quarter
UBX's debt is 46% greater than its equity
The company's debt to equity has surged by 118% YoY and by 33% QoQ
UBX's equity has dropped by 61% year-on-year and by 28% since the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.